Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities

Life Sciences

Volumn 76, Issue 13, 2005, Pages 1427-1437

  Sadée, Wolfgang ^a   Wang, Danxin ^a   Bilsky, Edward J ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Basal activity; Inverse agonist; Neutral antagonist; Opioid receptors

Indexed keywords

CALMODULIN; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT;

ANESTHESIA COMPLICATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG OVERDOSE; DRUG WITHDRAWAL; GENE CONTROL; HUMAN; LONG TERM CARE; NARCOTIC DEPENDENCE; NERVE CELL PLASTICITY; PHARMACODYNAMICS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 12844281159     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.10.024     Document Type: Review

References (58)

1. M.D. Aceto, L.S. Harris, and E.R. Bowman Etorphines: mu opioid receptor selective antinociception and low physical dependence capacity European Journal of Pharmacology 338 1997 215
2. R.A. Adan, and M.J. Kas Inverse agonism gains weight Trends in Pharmacological Sciences 24 2003 315 321
3. J.R. Arden, V. Segredo, Z. Wang, J. Lameh, and W. Sadée Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu opioid receptor expressed in HEK 293 cells Journal of Neurochemistry 65 1995 1636 1645
4. E.L. Barker, R.S. Westphal, D. Schmidt, and E. DSanders-Bush Constitutively active 5-hydroxytryptamine 2C receptors reveal novel inverse agonist activity of receptor ligands Journal of Biological Chemistry 269 1994 11687 11690
5. J.A.J. Becker, A. Wallace, A. Garzon, P. Ingallinella, E. Bianchi, R. Cortese, F. Simonin, B.L. Kieffer, and A. Pessi Ligands for k-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library Journal of Biological Chemistry 274 1999 27513 27522
6. M.M. Belcheva, M. Szucs, D. Wang, W. Sadée, and C.J. Coscia Mu opioid receptor-mediated ERK-activation involves calmodulin-dependent EGF receptor transactivation Journal of Biological Chemistry 276 2001 33847 33853
7. E.J. Bilsky, R.N. Bemstein, Z. Wang, W. Sadée, and F. Porreca Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice Journal of Pharmacology and Experimental Therapeutics 277 1996 487 490
8. E. Bofill-Cardona, O. Kudlacek, Q. Yang, H. Ahorn, M. Freissmuth, and C. Nanoff Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch Journal of Biological Chemistry 275 2000 32672 32680
9. L. Bohn, R. Gainetdinov, F. Lin, R.J. Lefkowitz, and M. Caron Mu opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence Nature 408 2000 720 723
10. L. Bohn, R.J. Lefkowitz, and M. Caron Differential mechanisms of morphine antinociceptive tolerance revealed in beta-arrestin-2 knock-out mice Journal of Neuroscience 22 2002 10494 10500
11. N. Burford, D. Wang, and W. Sadée G-protein coupling of mu-opioid receptor (OP3): elevated basal signaling activity Biochemical Journal 348 2000 531 537
12. T. Costa, and A. Herz Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins Proceedings of the National Academy of Sciences of the United States of America 86 1989 7321
13. S.L. Cruz, J.E. Villarreal, and N.D. Volkow Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal Life Science 58 1996 L381 PL389
14. G.H. Fan, L.Z. Wang, H.C. Qiu, L. Ma, and G. Pei Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence Molecular Pharmacology 56 1999 39
15. A. Ferrari, M. Bertolotti, A. DellUtri, U. Avico, and E. Sternieri Serum time course of naltrexone and 6-beta-naltrexol levels during long-term treatment in drug addicts Drug and Alcohol Dependence 52 1998 211 220
16. J. Foss A review of the potential role of methylnaltrexone in opioid bowel dysfunction American Journal of Surgery 182 5A Suppl 2001 19S 26S
17. F. Gbahou, A. Rouleau, S. Morisset, and R. Parmentier Protean agonism at histamine H3 receptors in vitro and in vivo Proceedings of the National Academy of Sciences of the United States of America 100 2003 11086 11091
18. S.R. George, B.F. O'Dowd, and S.P. Lee G-protein coupled receptor oligomerization and its potential for drug discovery Nature Reviews Drug Discovery 1 2002 808
19. L. Guarna, A. Barolini, C. Ghelardini, N. Galeotti, L. Bracci, G. Stefano, and E. Bianchi Anti-mu opioid antiserum against the third external loop of the cloned mu opioid receptor acts as a mu receptor neutral antagonist Molecular Brain Research 119 2003 100 110
20. L. Hollister, K. Johnson, D. Boukhabza, and H. Gillespie Aversive effects of naltrexone in subjects not dependent on opiates Drug and Alcohol Dependence 8 1981 37 41
21. A.A. Jensen, and T.A. Spalding Allosteric modulation of G-protein coupled receptors European Journal Pharmaceutical Sciences 21 2004 407 420
22. B.A. Jordan, and L.A. Devi G protein coupled receptor heterodimerization modulates receptor function Nature 399 1999 697 700
23. D.E. Keith, S.R. Murray, P.A. Zaki, P.C. Chu, D.V. Lissin, L. Kang, C.J. Evans, and M. von Zastrow Morphine activates opioid receptors without causing their rapid internalization Journal of Biological Chemistry 271 1996 19021 19024
24. T. Kenakin Principles: receptor theory in pharmacology Trends in Pharmacological Sciences 25 2004 186 192
25. T. Koch, T. Kroslak, P. Mayer, E. Raulf, and V. Hollt Site mutation in the rat mu-opioid receptor demonstrates the involvement of calcium/calmodulin- dependent protein kinase II in agonist-mediated desensitization Journal of Neurochemistry 69 1997 1767 1770
26. A. Kurz, and D. Sessler Opioid-induced bowel dysfunction: pathophysiology and potential new therapies Drugs 63 2003 649 671
27. R.J. Lefkowitz, S. Cotecchia, P. Samama, and T. Costa Constitutive activity of receptors couple to guanine nucleotide regulatory proteins Trends in Pharmacological Sciences 14 1993 303 307
28. J.G. Liu, and P.L. Prather Chronic exposure to mu opioid agonists produces constitutive activation of mu opioid receptors in direct proportion to the efficacy of the agonist used for the pretreatment Molecular Pharmacology 60 2001 53 62
29. J.G. Liu, M.B. Ruckle, and P.L. Prather The two-state model of receptor constitutively active mu opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist {D-Ala2, N-MePhe4, Gly-ol5} enkephalin Journal of Biological Chemistry 276 2001 37779 37786
30. W.E. Miller, D.A. Houtz, C.D. Nelson, P.E. Kolattukudy, and R.J. Lefkowitz G protein coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus U28 GPCR Journal of Biological Chemistry 278 2003 21663 21671
31. G. Milligan Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective Molecular Pharmacology 64 2003 1271 1276
32. R. Minakami, N. Jinnai, and H. Sugiyama Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro Journal of Biological Chemistry 272 1997 20291 20298
33. E.J. Nestler, and G.K. Aghajanian Molecular and cellular basis of drug addiction Science 278 1997 58 63
34. S. Ohmori, and Y. Morimoto Dihydroetorphine: a potent analgesic: pharmacology, toxicology, pharmacokinetics, and clinical effects CNS Drug Reviews 8 2002 391
35. L. Parker, and A. Joshi Naloxone-precipitated morphine withdrawal induced place aversions: effects of naloxone at 24 hours postmorphine Pharmacology, Biochemistry and Behavior 61 1998 331 333
36. M. Quillan, K.W. Carlson, C. Song, D. Wang, and W. Sadée Differential effects of mu opioid receptor (MOR) ligands on Ca2+ signaling Journal of Pharmacology and Experimental Therapeutics 302 2002 1002 1012
37. R. Romberg, E. Sarton, L. Tepperma, H. Matthes, B.L. Kieffer, and A. Dahan Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild-type and mu-opioid receptor deficient mice British Journal of Anaesthesia 91 2003 862 870
38. E. Ross, and T. Wilkie GTPasa-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins Annual Review of Biochemistry 69 2000 795 827
39. W.Z.W. Sadée, J.R. Arden, and V. Segredo Constitutive activation of the mu-opioid receptor: a novel paradigm of receptor regulation in narcotic analgesia, tolerance and dependence Analgesia 1 1994 11 14
40. P. Sanchez-Blazquez, M. Rodriquez-Diaz, A. Lopez-Fando, M. Rodriguez-Munoz, and J. Garzon The GBeta5 subunit that associates with the R7 subfamily of RGS proteins regulates mu-opioid effects Neuropharmacology 45 2003 82 95
41. M.A. Satnick, T.M. Suter, S.L. Gackenheimer, P.J. Emmerson, S.J. Quimby, D.R. Gehlert, W.J. Wheeler, and C.H. Mitch Na+-dependent high affinity binding of 3H-LY515300, a 3,4-dimethyl-4-3-hydroxyphenyl piperidine opioid receptor inverse agonist European Journal of Pharmacology 482 2003 139 150
42. R. Seifert, and K. Wenzel-Seifert Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors Naunyn-Schmiedeberg's Archives of Pharmacology 366 2002 381 416
43. L. Stinus, S. Caille, and G. Koob Opiate withdrawal-induced place aversion lasts for up to 16 weeks Psychopharmacology (Berl) 49 2000 115 120
44. M. Teitler, K. Herrick-Davis, and A. Purohit Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors Current Topics in Medicinal Chemistry 2 2002 529 539
45. G. Terman, W. Jin, Y. Cheong, J. Lowe, M. Caron, R. Lefkowitz, and C. Chavkin G-protein receptor kinase-3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal British Journal of Pharmacology 141 2003 55 64
46. J. Turner, A. Gelasco, and J. Raymond Calmodulin interacts with the third intracellular loop of the serotonin 5-HT1A receptor at two distinct sites Journal of Biological Chemistry 279 2004 17027 17037
47. D. Wang, J.M. Quillan, K. Winans, J.L. Lucas, and W. Sadée Single nucleotide polymorphisms in the human mu opioid receptor gene alter G protein coupling and calmodulin binding Journal of Biological Chemistry 276 2001 34624 34630
48. D. Wang, E.L. Raehal, E.J. Bilsky, and W. Sadée Inverse agonists and neutral antagonists at mu opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence Journal of Neurochemistry 77 2001 1590 1600
49. D. Wang, K. Raehal, E.T. Lin, B.L. Kieffer, and W. Sadée Basal mu opioid receptor signaling: possible role in narcotic dependence Journal of Pharmacology and Experimental Therapeutics 308 2004 512 520
50. D. Wang, L.M. Tolbert, K.W. Carlson, and W. Sadée Nuclear Ca2+/calmodulin translocation activated by mu opioid (OP3) receptor Journal of Neurochemistry 74 2000 1418 1425
51. D.X. Wang, W. Sadée, and J.M. Quillan Calmodulin binding to G protein-coupling domain of opioid receptors Journal of Biological Chemistry 274 1999 22081 22088
52. D.X. Wang, C.K. Surratt, and W. Sadée Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP3) in morphine-pretreated cells Journal of Neurochemistry 75 2000 763 771
53. Z. Wang, J. Arden, and W. Sadée Basal phosphorylation of mu opioid receptor is agonist modulated and Ca2+-dependent FEBS Letters 387 1996 53 57
54. Z. Wang, E.J. Bilsky, F. Porreca, and W. Sadée Constitutive Mu Opioid Receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence Life Sciences 54 1994 L339 L350
55. P.J. Welsby, E. Kellett, G. Wilkinson, and G. Milligan Enhanced detection of receptor constitutive activity in the presence of regulators of protein signaling: application to the detection and analysis of inverse agonists and low efficacy partial agonists Molecular Pharmacology 61 2002 1211 1221
56. Y. Yu, L. Zhang, X. Yin, H. Sun, G.R. Uhl, and J.B. Wang Mu opioid receptor phosphorylation, desensitization and ligand efficacy Journal of Biological Chemistry 272 1997 28869 28874
57. V. Zachariou, D. Georgescu, N. Sanchez, Z. Rahman, R. Dileone, O. Berton, R. Neve, L. Sim-Selley, D. Selley, S. Gold, and E. Nestler Essential role for RGS9 in opiate action Proceedings of the National Academy of Sciences of the United States of America 100 2003 13656 13661
58. J. Zhang, S. Ferhuson, L. Barak, S. Bodduluri, S. Laporte, P. Law, and M. Caron Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness Proceedings of the National Academy of Sciences of the United States of America 95 1998 7157 7162